Authors
Loading...
CRISPR silencing of HMGA1 disrupts immune escape in KMT2A-r AML, suggesting it as a target for therapy.
Thompson et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: